> Take me to the Patient area

Patient Info

Clinical Data Prof. Dr. Karl Glaessner 80 Years of Clinical Use ~4.6 Million Doses Sold per Year

LeciCircles1932In 1932, Prof. M.D. Glaessner detailed the development of a new type of laxative, a carbon dioxide releasing suppository. Trialling these suppositories in humans, he noted that the release of carbon dioxide triggered the passage of a normal stool in a short time period.1

LeciCircles1957Clauser et al. studied the effect of Lecicarbon suppositories versus placebo. This trial was performed, in part, to show how double-blind studies could be used to differentiate between placebo and active effects.

They found that in a double-blind clinical trial, Lecicarbon was effective in 66% of 134 patients compared with success in 10% of 48 patients in the placebo group.

One conclusion they drew on Lecicarbon was that Lecicarbon “supports a normal, daily reflex bowel pattern in a natural way through carbon dioxide production.”2

In 1974, Mund-Hoym studied the effectiveness and usefulness of Lecicarbon in 250 patients during a 2-year period. Mund-Hoym concluded that Lecicarbon had good safety and little risk of laxative dependency.

In addition, Lecicarbon was used in pre-/post-operative patients. Success rates for male and female adults were the same. The success  of relieving post-operative constipation in children was approximately 100% of patients in the trial.3

The study looked at 4 types of male and female patients with varying success.

Constipation Type
Former laxative abusers
Male/% success
Female/% success
Atonic constipation*1No9080
Spastic constipation*2No7060
*1 Chronic constipation associated with muscular activity; dehydrated stools.
*2 Chronic constipation as a result of suppressed defaecation reflex; more common in the elderly; can be associated with anal fissures, haemorrhoids, etc.

LeciCircles2009Lecicarbon used as part of a bowel cleansing procedure prior to tomographic colonography.4

LeciCircles2011Lecicarbon A (licensed for use in adults) and Lecicarbon C (licensed for use in children) were approved in the UK via the well-established use application.5

LeciCircles2012Lecicarbon E (the German equivalent of Lecicarbon A) was referenced as an available rectal stimulant in Guidelines for Neurogenic Bowel Dysfunction in individuals with Central Neurological Conditions.6

References: 1) K. Glaessner; Therapeutic studies on chronic (habitual) obstipation: Sonderabdruck aus Archiv fϋr Verdauungskranheiten, B.d. 52(1932) Heft 1/2, p44-49. 2) G. Clauser et al; Placebo Therapy of Obstipation and clinical trials of laxatives: Medizinische Klinik (Die Wochenschrift fϋr Klinik und Praxis) 52.Jg Nr.24 (1947) p1071-1073.  3) W.D. Mund-Hoym; Therapy for spastic and atonic obstipation without side effects Ǎrztliche Praxis XXVI. Jg Nr. 78 (1974) p3229.  4) S. Yamamoto et al; A simple image processing approach for electronic cleansing in computed tomographic colonography: Biomed Imaging Interv J 3 (2009) p28.  5) Lecicarbon A Suppository SmPC revised 01.08.2011.  6) Guidelines for management of neurogenic bowel dysfunction in individuals with central neurological conditions; MASCIP (2012).

For further information, please call: 01730 231148, email: info@aspirepharma.co.uk
or visit www.aspirepharma.co.uk

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148
For more information about Lecicarbon, please see full prescribing information.
Revision date 19 June 2015